Researcher
Pieter Van Der Veken
- Research Expertise:Medicinal chemistry & drug discovery, pharmaceutical chemistry, organic chemistry & organic synthesis
- Keywords:ORGANIC CHEMISTRY, MEDICINAL CHEMISTRY, DRUG DISCOVERY, Pharmacy and pharmacology
- Disciplines:(Bio)molecular modelling and design, Characterisation of biologically active (macro)molecules, Medicinal and biomolecular chemistry not elsewhere classified, Bio-organic chemistry, Organic chemical synthesis, Medicinal chemistry
- Research techniques:Drug design, organic synthesis, characterization of molecules via NMR spectroscopy, mass spectrometry and other analytical techniques
- Users of research expertise:Pharmaceutical and biotech-industry
Affiliations
- Medicinal Chemistry (UAMC) (Research group)
Member
From1 Oct 2003 → Today
Projects
41 - 50 of 74
- Novel Atg4B-inhibitors and dual [Atg4B-carbonic anhydrase] inhibitors for interfering with cytoprotective mechanisms of cancer cells in the acidic tumor micro-environment (ONCOPHAGY).From1 Apr 2017 → 31 Mar 2019Funding: H2020-EU.1.3.- EXCELLEN SCIENCE - Marie Skłodowska-Curie actions
- Discovery of necroptosis and ferroptosis inhibitors with potential applications in pathologies associated with regulated necrosis.From1 Oct 2016 → 30 Sep 2018Funding: FWO fellowships
- On-target assembly of druglike small molecules as protease inhibitors: a bottom-up approach using urokinase plasminogen activator (uPA) as a model target.From1 Oct 2016 → 30 Sep 2019Funding: FWO fellowships
- Validation of the oxadiazolone isostere as a carboxylate replacement in caspase inhibitors: approaches involving Strecker-based synthetic methodology development and on-target strategies.From1 Oct 2016 → 30 Sep 2018Funding: FWO fellowships
- On-target assembly of druglike small molecules: a bottom-up approach using urokinase plasminogen activator and caspase 1 as model targets.From1 Jan 2016 → 31 Dec 2019Funding: FWO research project (including WEAVE projects)
- "Hit-to-lead" optimization and biological characterization of novel anti-mycobacterials.From15 Jul 2015 → 14 Jul 2016Funding: BOF - Doctoral projects
- Synthesis and characterization of molecular imaging probes for fibroblast activation protein (FAP), dipeptidyl peptidase 9 (DPP9) and dipeptidyl peptidase 8 (DPP8), derived from selective inhibitors.From1 Jan 2015 → 31 Dec 2018Funding: IWT personal funding - strategic basic research grants
- Prolyl oligopeptidase: partners and pathways in neuronal function and neurodegeneration.From1 Jan 2015 → 31 Dec 2018Funding: FWO research project (including WEAVE projects)
- The Extracellular Matrix in Epileptogenesis (ECMED).From1 Jan 2015 → 31 Dec 2018Funding: H2020-EU.1.3.- EXCELLEN SCIENCE - Marie Skłodowska-Curie actions
- Medicinal Chemistry-Drug Discovery (ADDN).From1 Jan 2015 → 31 Dec 2020Funding: IOF - mandates, IOF - Industrial Research Fund
Publications
1 - 10 of 129
- UPLC-TQD-MS/MS method validation for quality control of alkaloid content in lepidium meyenii (Maca)-containing food and dietary supplements(2024)
Authors: Ngoc Thao Hien Le, Kenn Foubert, Mart Theunis, Tania Naessens, Murat Bozdag, Pieter Van Der Veken, Luc Pieters, Emmy Tuenter
Pages: 1 - 11 - Design and synthesis of selective DPP9 inhibitors(2024)
Authors: Siham Benramdane, Pieter Van Der Veken, Hans De Winter
Number of pages: 232 - Next generation fibroblast activation protein (FAP) targeting PET tracers(2023)
Authors: Christian B.M. Poulie, Vladimir Shalgunov, Filipe Elvas, Yentl Van Rymenant, Euy-Sung Moon, Umberto Maria Battisti, Joni De Loose, Ingrid De Meester, Frank Rösch, Pieter Van Der Veken, et al.
Pages: 1 - 10 - From PERK to RIPK1(2023)
Authors: Camilla Scarpellini, Sophie Valembois, Kenneth Goossens, Mike Vadi, Caroline Lanthier, Greta Klejborowska, Pieter Van Der Veken, Hans De Winter, Mathieu J.M. Bertrand, Koen Augustyns
Pages: 1 - 15 - Novel generation of FAP inhibitor-based homodimers for improved application in radiotheranostics(2023)
Authors: Marcel Martin, Sanjana Ballal, Madhav Prasad Yadav, Chandrasekhar Bal, Yentl Van Rymenant, Joni De Loose, Emile Verhulst, Ingrid De Meester, Pieter Van Der Veken, Frank Roesch
Pages: 1 - 25 - Characterization of structurally diverse ¹⁸F-labeled d-TCO derivatives as a PET probe for bioorthogonal pretargeted imaging(2023)
Authors: Karuna Adhikari, Christel Vangestel, Pieter Van Der Veken, Sigrid Stroobants, Filipe Elvas, Koen Augustyns
Pages: 38252 - 38262 - Chemically diverse activity-based probes with unexpected inhibitory mechanisms targeting trypsin-like serine proteases(2023)
Authors: Alba Ramos Llorca, Lisse Decraecker, Valerie Cacheux, Irena Zeiburlina, Michelle De bruyn, Louise Battut, Carlos Moreno Cinos, Davide Ceradini, Eric Espinosa, Gilles Dietrich, et al.
Pages: 1 - 17 - Design, synthesis and evaluation of novel activity-based probes and inhibitors for trypsin-like serine proteases(2023)
Authors: Alba Ramos Llorca, Koen Augustyns, Pieter Van Der Veken
Number of pages: 289 - Highly selective inhibitors of dipeptidyl peptidase 9 (DPP9) derived from the clinically used DPP4-inhibitor vildagliptin(2023)
Authors: Siham Benramdane, Joni De Loose, Nicolò Filippi, Margarida Florindo Espadinha, Olivier Beyens, Yentl Van Rymenant, Laura Dirkx, Murat Bozdag, Koen Augustyns, Guy Caljon, et al.
Pages: 12717 - 12738 - Vildagliptin‐derived dipeptidyl peptidase 9 (DPP9) inhibitors(2022)
Authors: Siham Benramdane, Joni De Loose, Olivier Beyens, Yentl Van Rymenant, Gwendolyn Vliegen, Koen Augustyns, Hans De Winter, Ingrid De Meester, Pieter Van Der Veken
Pages: 1 - 16
Patents
1 - 10 of 10
- 3-(Benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.g. Stroke (Inventor)
- Bis(acetamidophenyl) guanidinophenyethylphosphonates for use in the prevention and/or treatment of PAR-related diseases. (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.G. stroke (Inventor)
- Halogenated benzotropolones as ATG4B inhibitors (Inventor)
- Halogenated benzotropolones as atg4b inhibitors (Inventor)
- 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.G. stroke (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- KLK4 inhibitors (Inventor)